Section of Cardiovascular Medicine, Department of Medicine, Yale Translational Research Imaging Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Department of Biomedical Engineering, Yale University, School of Engineering and Applied Science, New Haven, CT, 06520, USA.
J Nucl Cardiol. 2022 Apr;29(2):663-676. doi: 10.1007/s12350-020-02317-8. Epub 2020 Aug 20.
We have set out to develop a catheter-based theranostic system that: (a) identifies diseased and at-risk myocardium via endocardial detection of systemically delivered β-emitting radiotracers and (b) utilizes molecular signals to guide delivery of therapeutics to appropriate tissue via direct intramyocardial injection.
Our prototype device consists of a miniature β-radiation detector contained within the tip of a flexible intravascular catheter. The catheter can be adapted to incorporate an injection port and retractable needle for therapeutic delivery. The performance of the β-detection catheter was assessed in vitro with various β-emitting radionuclides and ex vivo in hearts of pigs following systemic injection of F-fluorodeoxyglucose (F-FDG) at 1-week post-myocardial infarction. Regional catheter-based endocardial measurements of F activity were compared to regional tissue activity from PET/CT images and gamma counting.
The β-detection catheter demonstrated sensitive in vitro detection of β-radiation from Na (β), F (β), and Tl (β), with minimal sensitivity to γ-radiation. For F, the catheter demonstrated a sensitivity of 4067 counts/s/μCi in contact and a spatial resolution of 1.1 mm FWHM. Ex vivo measurements of endocardial F activity with the β-detection catheter in the chronic pig infarct model demonstrated good qualitative and quantitative correlation with regional tissue activity from PET/CT images and gamma counting.
The prototype β-detection catheter demonstrates sensitive and selective detection of β and β emissions over a wide range of energies and enables high-fidelity ex vivo characterization of endocardial activity from systemically delivered F-FDG.
我们开发了一种基于导管的治疗诊断系统,该系统:(a)通过心内膜检测全身递送的β发射放射性示踪剂来识别患病和高危心肌;(b)利用分子信号通过直接心肌内注射将治疗药物引导至适当的组织。
我们的原型设备由微型β辐射探测器组成,位于柔性血管内导管的尖端内。该导管可适应于包含注射端口和可缩回的针,用于治疗药物的输送。通过将各种β发射放射性核素和 F-氟脱氧葡萄糖(F-FDG)全身注射后 1 周的猪心进行离体实验,评估了β检测导管的性能。将基于导管的心内膜 F 活性的局部测量值与来自 PET/CT 图像和伽马计数的局部组织活性进行比较。
β检测导管在体外对 Na(β)、F(β)和 Tl(β)的β辐射具有灵敏的检测能力,对γ辐射的敏感性最小。对于 F,导管在接触时的灵敏度为 4067 计数/s/μCi,空间分辨率为 1.1mm FWHM。在慢性猪梗塞模型中,β检测导管对心内膜 F 活性的离体测量与来自 PET/CT 图像和伽马计数的局部组织活性具有良好的定性和定量相关性。
原型β检测导管在广泛的能量范围内灵敏且选择性地检测β和β发射,并能够对全身递送的 F-FDG 的心内膜活性进行高保真度的离体特征描述。